Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease

Neurology

Volumn 85, Issue 1, 2015, Pages 40-47

  Goetzl, Edward J ^a   Boxer, Adam ^a   Schwartz, Janice B ^b   Abner, Erin L ^c   Petersen, Ronald C ^d   Miller, Bruce L ^a   Kapogiannis, Dimitrios ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d MAYO CLINIC   (United States)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; CD81 ANTIGEN; HEAT SHOCK PROTEIN 70; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NERVE CELL ADHESION MOLECULE L1; NERVE CELL ADHESION MOLECULE L1 ANTIBODY; PROTEIN ANTIBODY; UBIQUITIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CTSD PROTEIN, HUMAN; LAMP1 PROTEIN, HUMAN; LYSOSOMAL PROTEINS; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOLYSOSOME; AUTOPHAGY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; IMMUNOADSORPTION; MALE; MILD COGNITIVE IMPAIRMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; BLOOD; EARLY DIAGNOSIS; LONGITUDINAL STUDY; METABOLISM; NERVE CELL;

ALZHEIMER DISEASE; BIOMARKERS; CATHEPSIN D; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; EXOSOMES; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMANS; LONGITUDINAL STUDIES; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; MALE; NEURONS; PROTEINS; RETROSPECTIVE STUDIES;

EID: 84937020256     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001702     Document Type: Article

References (31)

1. Fiandaca MS, Kapogiannis D, Mapstone M, et al. Identification of preclinical Alzheimers disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement Epub 2014 Aug 14
2. Kapogiannis D, Boxer A, Schwartz JB, et al. Dysfunctionally phosphorylated IRS-1 in neural derived blood exosomes of preclinical Alzheimers disease. FASEB J 2015; 29: 589-596
3. Ihara Y, Morishima-Kawashima M, Nixon R. The ubiquitin-proteasome system and the autophagiclysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2: a006361
4. Schwagerl AL, Mohan PS, Cataldo AM, Vonsattel JP, Kowall NW, Nixon RA. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J Neurochem 1995; 64: 443-446
5. Nixon RA, Cataldo AM. Lysosomal system pathways: genes to neurodegeneration in Alzheimers disease. J Alzheimers Dis 2006; 9: 277-289
6. Urbanelli L, Magini A, Buratta S, et al. Signaling pathways in exosomes biogenesis, secretion and fate. Genes 2013; 4: 152-170
7. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256: 183-194
8. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association Workgroups on Diagnostic Guidelines for Alzheimers Disease. Alzheimers Dement 2011; 7: 280-292
9. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimers disease: revising the NINCDSADRDA criteria. Lancet Neurol 2007; 6: 734-746
10. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimers disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimers Disease. Neurology 1984; 34: 939-944
11. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimers disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413
12. Irizarry MC, Webb DJ, Bains C, et al. Predictors of placebo group decline in the Alzheimers Disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimers disease. J Alzheimers Dis 2008; 14: 301-311
13. Cano SJ, Posner HB, Moline ML, et al. The ADAS-cog in Alzheimers disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry 2010; 81: 1363-1368
14. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456-2477
15. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology 2011; 76: 1006-1014
16. Faust PL, Kornfeld S, Chirgwin JM. Cloning and sequence analysis of cDNA for human cathepsin D. Proc Natl Acad Sci USA 1985; 82: 4910-4914
17. Benes P, Vetvicka V, Fusek M. Cathepsin D: many functions of one aspartic protease. Crit Rev Oncol Hematol 2008; 68: 12-28
18. Masson O, Bach AS, Derocq D, et al. Pathophysiological functions of cathepsin D: targeting its catalytic activity versus its protein binding activity? Biochimie 2010; 92: 1635-1643
19. Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-Talk between the ubiquitin-proteasome and autophagy-lysosome systems. FEBS Lett 2010; 584: 1393-1398
20. Kim S, Ock J, Kim AK, et al. Neurotoxicity of microglial cathepsin D revealed by secretome analysis. J Neurochem 2007; 103: 2640-2650
21. Demirel O, Jan I, Wolters D, et al. The lysosomal polypeptide transporter TAPL is stabilized by interaction with LAMP-1 and LAMP-2. J Cell Sci 2012; 125: 4230-4240
22. Bingol B, Sheng M. Deconstruction for reconstruction: the role of proteolysis in neural plasticity and disease. Neuron 2011; 69: 22-32
23. Ohsumi Y. Molecular dissection of autophagy: two ubiquitin-like systems. Nat Rev Mol Cell Biol 2001; 2: 211-216
24. Weidberg H, Shvets E, Elazar Z. Biogenesis and cargo selectivity of autophagosomes. Annu Rev Biochem 2011; 80: 125-156
25. Wegele H, Muller L, Buchner J. Hsp70 and Hsp90: a relay team for protein folding. Rev Physiol Biochem Pharmacol 2004; 151: 1-44
26. Jinwal UK, Akoury E, Abisambra JF, et al. Imbalance of Hsp70 family variants fosters tau accumulation. FASEB J 2013; 27: 1450-1459
27. Nylandsted J, Gyrd-Hansen M, Danielewicz A, et al. Heat shock protein 70 promotes cell survival by inhibiting lysosomal membrane permeabilization. J Exp Med 2004; 200: 425-435
28. Beere HM, Wolf BB, Cain K, et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat Cell Biol 2000; 2: 469-475
29. Lancaster GI, Febbraio MA. Exosome-dependent trafficking of HSP70: a novel secretory pathway for cellular stress proteins. J Biol Chem 2005; 280: 23349-23355
30. Alvarez-Erviti L, Seow Y, Schapira AH, et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis 2011; 42: 360-367
31. Goetzl EJ, Boxer A, Schwartz JB, et al. Low neural exosomal levels of cellular survival factors in Alzheimers disease. Ann Clin Transl Neurol 2015. doi: 10.1002/acn3.211